S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
S&P 500   4,544.90
DOW   35,677.02
QQQ   374.10
NASDAQ:ALNY

Alnylam Pharmaceuticals Short Interest Ratio and Short Volume

$198.61
-5.72 (-2.80 %)
(As of 10/22/2021 04:00 PM ET)
Add
Compare
Today's Range
$198.36
$205.17
50-Day Range
$177.08
$209.29
52-Week Range
$119.29
$212.00
Volume481,274 shs
Average Volume618,203 shs
Market Capitalization$23.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.22

Alnylam Pharmaceuticals (NASDAQ:ALNY) Short Interest Data

Current Short Volume4,010,000 shares
Previous Short Volume4,420,000 shares
Change Vs. Previous Month-9.28%
Dollar Volume Sold Short$757.13 million
Short Interest Ratio / Days to Cover6.7
Last Record DateSeptember, 30 2021
Outstanding Shares118,848,000 shares
Percentage of Shares Shorted3.37%
Today's Trading Volume481,274 shares
Average Trading Volume618,203 shares
Today's Volume Vs. Average-22.15%

Days to Cover Over Time

Percentage of Float Shorted Over Time

cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook
Short Selling Alnylam Pharmaceuticals ?

Sign up to receive the latest short interest report for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE newsletter.

Alnylam Pharmaceuticals (NASDAQ:ALNY) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
9/30/20214,010,000 shares $757.13 million -9.3%N/A6.7 $188.81
9/15/20214,420,000 shares $828.66 million -8.5%N/A7 $187.48
8/31/20214,830,000 shares $972.91 million -3.6%N/A7.2 $201.43
8/13/20215,010,000 shares $984.67 million -1.0%N/A7.3 $196.54
7/30/20215,060,000 shares $905.44 million +19.9%N/A7.7 $178.94
7/15/20214,220,000 shares $725.63 million -2.3%3.6%6.8 $171.95
6/30/20214,320,000 shares $732.33 million -6.7%3.7%7.2 $169.52
6/15/20214,630,000 shares $770.90 million +9.2%4.0%8.7 $166.50
5/28/20214,240,000 shares $602.04 million -6.2%3.7%8.6 $141.99
5/14/20214,520,000 shares $600.80 million +9.4%N/A9.1 $132.92
4/30/20214,130,000 shares $576.92 million +0.7%N/A7.7 $139.69
4/15/20214,100,000 shares $567.07 million +12.3%N/A7 $138.31
3/31/20213,650,000 shares $493.22 million -1.9%N/A5.3 $135.13
3/15/20213,720,000 shares $528.98 million +0.5%N/A5.2 $142.20
2/26/20213,700,000 shares $542.38 million +5.1%N/A5.4 $146.59
2/12/20213,520,000 shares $582.14 million -4.9%N/A5.2 $165.38
1/29/20213,700,000 shares $572.54 million -4.4%N/A5.4 $154.74
1/15/20213,870,000 shares $638.82 million +10.9%N/A5.9 $165.07
12/31/20203,490,000 shares $457.33 million -4.6%N/A6.4 $131.04
12/15/20203,660,000 shares $485.65 million -3.2%N/A7.2 $132.69
11/30/20203,780,000 shares $490.87 million +1.3%N/A7.4 $129.86
11/15/20203,730,000 shares $505.45 million +3.9%N/A7.2 $135.51
10/30/20203,590,000 shares $442.72 million +5.9%N/A7.5 $123.32
10/15/20203,390,000 shares $487.85 million +4.0%N/A7.3 $143.91
9/30/20203,260,000 shares $474.66 million -9.2%N/A6.6 $145.60

Institutional Investors Shorting Alnylam Pharmaceuticals (NASDAQ:ALNY)

This table shows institutional investors, funds, and major shareholders that have reported short positions as of their most recent reporting period. Most commonly, these investors have purchased put options on shares of Alnylam Pharmaceuticals. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Reporting DateInvestor NameShares Shorted (Previous)Shares Shorted (Current)Position ChangePosition Size
9/13/2021Bank of America Corp DEN/A39,800N/A$6,747.00
8/20/2021Jefferies Group LLCN/A20,000N/A$3,390.00
8/18/2021Ikarian Capital LLCN/A300,000N/A$50,856.00
8/17/2021Walleye Trading LLC2,00029,900+1,395.0%$5,069.00
8/17/2021Parallax Volatility Advisers L.P.N/A25,000N/A$4,238.00
8/17/2021Balyasny Asset Management LLCN/A169,000N/A$28,649.00
8/17/2021Boothbay Fund Management LLCN/A34,100N/A$5,781.00
8/17/2021Citadel Advisors LLC26,20086,000+228.2%$14,579.00
8/16/2021Squarepoint Ops LLC64,6001,900-97.1%$322.00
8/16/2021Bank of America Corp DEN/A39,800N/A$6,747.00
8/16/2021SG3 Management LLC12,50015,000+20.0%$2,543.00
8/16/2021Credit Suisse AG74,60028,500-61.8%$4,831.00
8/16/2021Jefferies Group LLCN/A2,000,000N/A$3,390.00
8/16/2021Nuveen Asset Management LLCN/A31,000N/A$5.00
8/16/2021Goldman Sachs Group Inc.30,00029,000-3.3%$4,916.00
8/13/2021PEAK6 Investments LLCN/A25,000N/A$4,238.00
8/12/2021JPMorgan Chase & Co.N/A35,000N/A$5,933.00
8/12/2021Simplex Trading LLC16733,500+19,959.9%$5,678.00
8/12/2021Twin Tree Management LPN/A1,500N/A$254.00
8/11/2021Susquehanna International Group LLP101,200229,600+126.9%$38,922.00
8/6/2021Wolverine Trading LLC8,70026,500+204.6%$4,396.00
7/31/2021Cutler Group LPN/A9,500N/A$76.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) Short Interest FAQ













Alnylam Pharmaceuticals (NASDAQ:ALNY) Short Interest Frequently Asked Questions

What is Alnylam Pharmaceuticals' current short interest?

Short interest is the volume of Alnylam Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of September 30th, investors have sold 4,010,000 shares of ALNY short. Learn More on Alnylam Pharmaceuticals' current short interest.

What is a good short interest ratio for Alnylam Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Alnylam Pharmaceuticals currently has a short interest ratio of 7.0. Learn More on a good short interest ratio for Alnylam Pharmaceuticals

Which institutional investors are shorting Alnylam Pharmaceuticals?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Alnylam Pharmaceuticals: Bank of America Corp DE, Jefferies Group LLC, Ikarian Capital LLC, Walleye Trading LLC, Parallax Volatility Advisers L.P., Balyasny Asset Management LLC, Boothbay Fund Management LLC, Citadel Advisors LLC, Squarepoint Ops LLC, Bank of America Corp DE, SG3 Management LLC, Credit Suisse AG, Jefferies Group LLC, Nuveen Asset Management LLC, Goldman Sachs Group Inc., PEAK6 Investments LLC, JPMorgan Chase & Co., Simplex Trading LLC, Twin Tree Management LP, Susquehanna International Group LLP, Wolverine Trading LLC, and Cutler Group LP. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Alnylam Pharmaceuticals' short interest increasing or decreasing?

Alnylam Pharmaceuticals saw a decline in short interest in September. As of September 30th, there was short interest totaling 4,010,000 shares, a decline of 9.3% from the previous total of 4,420,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Alnylam Pharmaceuticals' short interest compare to its competitors?

0.00% of Alnylam Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sub-industry of "biotechnology" compare to Alnylam Pharmaceuticals: Amgen Inc. (1.96%), Gilead Sciences, Inc. (0.00%), Regeneron Pharmaceuticals, Inc. (1.76%), Vertex Pharmaceuticals Incorporated (1.97%), Biogen Inc. (1.68%), Seagen Inc. (1.78%), Exact Sciences Co. (0.00%), Repligen Co. (3.29%), Incyte Co. (2.52%), and BioMarin Pharmaceutical Inc. (5.96%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: S&P Global Inc. ($7.35 billion), Advanced Micro Devices, Inc. ($6.43 billion), Charter Communications, Inc. ($5.68 billion), Wayfair Inc. ($4.48 billion), Uber Technologies, Inc. ($3.77 billion), Canadian Pacific Railway Limited ($3.73 billion), Palo Alto Networks, Inc. ($3.10 billion), Zoom Video Communications, Inc. ($2.87 billion), Match Group, Inc. ($2.83 billion), and DoorDash, Inc. ($2.54 billion). View all of the most shorted stocks.

What does it mean to sell short Alnylam Pharmaceuticals stock?

Short selling ALNY is an investing strategy that aims to generate trading profit from Alnylam Pharmaceuticals as its price is falling. Alnylam Pharmaceuticals' stock is trading down $5.72 today. To short Alnylam Pharmaceuticals stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Alnylam Pharmaceuticals will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Alnylam Pharmaceuticals?

A short squeeze for Alnylam Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ALNY, which in turn drives the price of the stock up even further.

How often is Alnylam Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALNY, twice per month. The most recent reporting period available is September, 30 2021.



This page was last updated on 10/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.